Crosstalk between the renin-angiotensin system and the advance glycation end product axis in the heart: Role of the cardiac fibroblast

Journal of Cardiovascular Translational Research

Volumn 5, Issue 6, 2012, Pages 805-813

  Yamazaki, Katrina Go ^a   Gonzalez, Eileen ^a   Zambon, Alexander C ^b,c  

^a CALIFORNIA STATE UNIVERSITY   (United States)

^b San Diego   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Advanced glycation end products; Cardiac fibroblasts; Diabetic cardiomyopathy; Renin angiotensin system

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; GLUCOSE; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN RECEPTOR;

ARTICLE; CARDIAC FIBROBLAST; CARDIOVASCULAR RISK; CELL FUNCTION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; EXTRACELLULAR MATRIX; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; FIBROSIS; HEART MUSCLE; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; DIABETIC CARDIOMYOPATHIES; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MYOCARDIUM; RECEPTOR CROSS-TALK; RECEPTORS, IMMUNOLOGIC; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84878172907     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-012-9405-4     Document Type: Article

References (48)

1. Carey, R. M.; & Siragy, H. M. (2003). Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocrine Reviews, 24(3), 261-271.
2. Unger, T.; Paulis, L.; & Sica, D. A. Therapeutic perspectives in hypertension: Novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. European Heart Journal, 32(22), 2739-2747. doi: 10.1093/eurheartj/ehr253.
3. Paul, M.; Poyan Mehr, A.; & Kreutz, R. (2006). Physiology of local renin-angiotensin systems. Physiological Reviews, 86(3), 747-803. doi: 10.1152/physrev.00036.2005.
4. Ma, T. K.; Kam, K. K.; Yan, B. P.; & Lam, Y. Y. Renin-angiotensin- aldosterone system blockade for cardiovascular diseases: Current status. British Journal of Pharmacology, 160(6), 1273-1292. doi: 10.1111/j.1476-5381.2010. 00750.x.
5. Dostal, D. E.; & Baker, K. M. (1999). The cardiac renin-angiotensin system: Conceptual, or a regulator of cardiac function? Circulation Research, 85(7), 643-650.
6. Gray, M. O.; Long, C. S.; Kalinyak, J. E.; Li, H. T.; & Karliner, J. S. (1998). Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovascular Research, 40(2), 352-363.
7. Buhler, F. R.; Bolli, P.; Kiowski, W.; Erne, P.; Hulthen, U. L.; & Block, L. H. (1984). Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients. American Journal of Medicine, 77(2A), 36-42.
8. Weiss, D.; Sorescu, D.; & Taylor, W. R. (2001). Angiotensin II and atherosclerosis. The American Journal of Cardiology, 87(8A), 25C-32C.
9. Weiss, D.; Kools, J. J.; & Taylor, W. R. (2001). Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation, 103(3), 448-454.
10. Brown, R. D.; Ambler, S. K.; Mitchell, M. D.; & Long, C. S. (2005). The cardiac fibroblast: Therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and Toxicology, 45, 657-687. doi: 10.1146/annurev.pharmtox.45.120403.095802.
11. Iwata, M.; Cowling, R. T.; Yeo, S. J.; & Greenberg, B. Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. Journal of Molecular and Cellular Cardiology, 51(4), 542-547. doi: 10.1016/j.yjmcc.2010.12.003.
12. Singh, V. P.; Baker, K. M.; & Kumar, R. (2008). Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: Role in extracellular matrix production. American Journal of Physiology. Heart and Circulatory Physiology, 294(4), H1675-H1684. doi: 10.1152/ajpheart.91493. 2007.
13. Kim, N. N.; Villarreal, F. J.; Printz, M. P.; Lee, A. A.; & Dillmann, W. H. (1995). Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. American Journal of Physiology, 269(3 Pt 1), E426-E437.
14. Asbun, J.; & Villarreal, F. J. (2006). The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. Journal of the American College of Cardiology, 47(4), 693-700. doi: 10.1016/j.jacc.2005.09.050.
15. Vlassara, H.; & Palace, M. R. (2002). Diabetes and advanced glycation endproducts. Journal of Internal Medicine, 251(2), 87-101.
16. Asbun, J.; Manso, A. M.; & Villarreal, F. J. (2005). Profibrotic influence of high glucose concentration on cardiac fibroblast functions: Effects of losartan and vitamin E. American Journal of Physiology. Heart and Circulatory Physiology, 288(1), H227-H234. doi: 10.1152/ajpheart.00340.2004.
17. Aronson, D. (2003). Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension, 21(1), 3-12. doi: 10.1097/01.hjh.0000042892.24999.92.
18. Cooper, M. E. (2004). Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. American Journal of Hypertension, 17(12 Pt 2), 31S-38S. doi: 10.1016/j.amjhyper.2004.08.021.
19. Huebschmann, A. G.; Regensteiner, J. G.; Vlassara, H.; & Reusch. (2006). Diabetes and advanced glycoxidation end products. Diabetes Care, 29(6), 1420-1432. doi: 10.2337/dc05-2096.
20. Goldin, A.; Beckman, J. A.; Schmidt, A. M.; & Creager, M. A. (2006). Advanced glycation end products: Sparking the development of diabetic vascular injury. Circulation, 114(6), 597-605. doi: 10.1161/CIRCULATIONAHA.106.621854.
21. Stern, D. M.; Yan, S. D.; Yan, S. F.; & Schmidt, A. M. (2002). Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Research Reviews, 1(1), 1-15.
22. Bierhaus, A.; Humpert, P. M.; Morcos, M.; Wendt, T.; Chavakis, T.; Arnold, B.; Stern, D. M.; & Nawroth, P. P. (2005). Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine (Berlin), 83(11), 876-886. doi: 10.1007/s00109-005-0688-7.
23. Steckelings, U. M.; Rompe, F.; Kaschina, E.; & Unger, T. (2009). The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundamental and Clinical Pharmacology, 23(6), 693-703. doi: 10.1111/j.1472-8206.2009.00780.x.
24. Huang, J. S.; Guh, J. Y.; Hung, W. C.; Yang, M. L.; Lai, Y. H.; Chen, H. C.; & Chuang, L. Y. (1999). Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. The Biochemical Journal, 342(Pt 1), 231-238.
25. Souders, C. A.; Bowers, S. L.; & Baudino, T. A. (2009). Cardiac fibroblast: The renaissance cell. Circulation Research, 105(12), 1164-1176. doi: 10.1161/CIRCRESAHA.109.209809.
26. Liu, X.; Ostrom, R. S.; & Insel, P. A. (2004). cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. American Journal of Physiology. Cell Physiology, 286(5), C1089-C1099. doi: 10.1152/ajpcell.00461.2003.
27. Madani, S.; De Girolamo, S.; Munoz, D. M.; Li, R. K.; & Sweeney, G. (2006). Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovascular Research, 69(3), 716-725. doi: 10.1016/j.cardiores.2005.11.022.
28. Roberts, A. B.; Sporn, M. B.; Assoian, R. K.; Smith, J. M.; Roche, N. S.; Wakefield, L. M.; Heine, U. I.; Liotta, L. A.; Falanga, V.; Kehrl, J. H.; et al. (1986). Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 83(12), 4167-4171.
29. Iwata, M.; Cowling, R. T.; Gurantz, D.; Moore, C.; Zhang, S.; Yuan, J. X.; & Greenberg, B. H. (2005). Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. American Journal of Physiology. Heart and Circulatory Physiology, 289(6), H2356-H2363. doi: 10.1152/ajpheart.00317.2005.
30. Zahradka, P.; Werner, J. P.; Buhay, S.; Litchie, B.; Helwer, G.; & Thomas, S. (2002). NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. Journal of Molecular and Cellular Cardiology, 34(12), 1609-1621.
31. Meszaros, J. G.; Gonzalez, A. M.; Endo-Mochizuki, Y.; Villegas, S.; Villarreal, F.; & Brunton, L. L. (2000). Identification of G protein-coupled signaling pathways in cardiac fibroblasts: Cross talk between G(q) and G(s). American Journal of Physiology. Cell Physiology, 278(1), C154-C162.
32. Kumar, U. Cross-talk and modulation of signaling between somatostatin and growth factor receptors. Endocrine, 40(2), 168-180. doi: 10.1007/s12020-011- 9524-8.
33. Olivares-Reyes, J. A.; Shah, B. H.; Hernandez-Aranda, J.; Garcia-Caballero, A.; Farshori, M. P.; Garcia-Sainz, J. A.; & Catt, K. J. (2005). Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Molecular Pharmacology, 68(2), 356-364. doi: 10.1124/mol.104.010637.
34. Kamioka, M.; Ishibashi, T.; Sugimoto, K.; Uekita, H.; Nagai, R.; Sakamoto N, et al. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. Journal of Atherosclerosis and Thrombosis, 17(6), 590-600.
35. Hattori, Y.; Suzuki, M.; Hattori, S.; & Kasai, K. (2002). Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension, 39(1), 22-28.
36. Forbes, J. M.; Thorpe, S. R.; Thallas-Bonke, V.; Pete, J.; Thomas, M. C.; Deemer, E. R.; Bassal, S.; El-Osta, A.; Long, D. M.; Panagiotopoulos, S.; Jerums, G.; Osicka, T. M.; & Cooper, M. E. (2005). Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. Journal of the American Society of Nephrology, 16(8), 2363-2372. doi: 10.1681/ASN.2005010062.
37. Nakamura, K.; Yamagishi, S.; Nakamura, Y.; Takenaka, K.; Matsui, T.; Jinnouchi, Y.; & Imaizumi, T. (2005). Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvascular Research, 70(3), 137-141. doi: 10.1016/j.mvr.2005.10.002.
38. Tang, M.; Zhong, M.; Shang, Y.; Lin, H.; Deng, J.; Jiang, H.; Lu, H.; Zhang, Y.; & Zhang, W. (2008). Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cellular and Molecular Life Sciences, 65(18), 2924-2932. doi: 10.1007/s00018-008-8255-3.
39. Huang, J. S.; Guh, J. Y.; Chen, H. C.; Hung, W. C.; Lai, Y. H.; & Chuang, L. Y. (2001). Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cellular Biochemistry, 81(1), 102-113. doi:10.1002/1097-4644(20010401)81:1<102::AID-JCB1027>3.0.CO;2-Y.
40. Forbes, J. M.; Thomas, M. C.; Thorpe, S. R.; Alderson, N. L.; & Cooper, M. E. (2004). The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney International. Supplement, 92, S105-S107. doi: 10.1111/j.1523-1755.2004. 09225.x.
41. Ban, C. R.; & Twigg, S. M. (2008). Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers. Vascular Health and Risk Management, 4(3), 575-596.
42. Daoud, S.; Schinzel, R.; Neumann, A.; Loske, C.; Fraccarollo, D.; Diez, C.; & Simm, A. (2001). Advanced glycation endproducts: Activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Molecular Medicine, 7(8), 543-551.
43. Henry, R. M.; Paulus, W. J.; Kamp, O.; Kostense, P. J.; Spijkerman, A. M.; Dekker, J. M.; Nijpels, G.; Heine, R. J.; Bouter, L. M.; & Stehouwer, C. D. (2008). Deteriorating glucose tolerance status is associated with left ventricular dysfunction - the Hoorn Study. The Netherlands Journal of Medicine, 66(3), 110-117.
44. Mizushige, K.; Yao, L.; Noma, T.; Kiyomoto, H.; Yu, Y.; Hosomi, N.; Ohmori, K.; & Matsuo, H. (2000). Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation, 101(8), 899-907.
45. Reddy, V. S.; Harskamp, R. E.; van Ginkel, M. W.; Calhoon, J.; Baisden, C. E.; Kim, I. S.; Valente, A. J.; & Chandrasekar, B. (2008). Interleukin-18 stimulates fibronectin expression in primary human cardiac fibroblasts via PI3K-Akt-dependent NF-kappaB activation. Journal of Cellular Physiology, 215(3), 697-707. doi: 10.1002/jcp.21348.
46. Wolf, G.; Wenzel, U.; Burns, K. D.; Harris, R. C.; Stahl, R. A.; & Thaiss, F. (2002). Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney International, 61(6), 1986-1995. doi: 10.1046/j.1523-1755.2002.00365.x.
47. Lee, C. I.; Guh, J. Y.; Chen, H. C.; Hung, W. C.; Yang, Y. L.; & Chuang, L. Y. (2005). Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells. Journal of Cellular Biochemistry, 95(2), 281-292. doi: 10.1002/jcb.20380.
48. Bierhaus, A.; Chevion, S.; Chevion, M.; Hofmann, M.; Quehenberger, P.; Illmer, T.; Luther, T.; Berentshtein, E.; Tritschler, H.; Muller, M.; Wahl, P.; Ziegler, R.; & Nawroth, P. P. (1997). Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes, 46(9), 1481-1490.